secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001701541-25-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027
--------------------------------------------------------------------------------

- Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.
- Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.
- Guidance: cash sufficient to fund operations into Q4 2027.
- Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.
- Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/0001701541-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/bdtx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001701541-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer